Company Overview and News
Welcome to the OpGen Third Quarter 2017 Conference Call. At this time all participants are in a listen-only mode. Following management’s prepared remarks, we’ll hold a Q&A session. [Operator Instructions] As a reminder, this conference is being recorded, November 7, 2017. (46-3)
If you want a Stock Review on OPGN, TEAR, TROV, or PRAH then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. DailyStockTracker.com has issued research reports on OpGen Inc. (NASDAQ: OPGN), TearLab Corp. (NASDAQ: TEAR), TrovaGene Inc. (NASDAQ: TROV), and PRA Health Sciences Inc. (NASDAQ: PRAH). Medical Laboratories and Research companies focus on performing various tests on patients that give them information on patients' health. (124-0)
Welcome to the OpGen Second Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks we will hold a Q&A session. [Operator Instructions] As a reminder, this conference is being recorded, August 8, 2017.
July 25, 2017 - jVen Capital, LLC has filed a SC 13D/A form disclosing ownership of 9,385,948 shares of OpGen, Inc. (NASDAQ:OPGN) corresponding to a(n) 17.77 ownership percentage.
Pfizer Inc. (NYSE:PFE) stock shows rises of 0.78% and traded at a price of $33.62 in preceding trading session. Pfizer Inc. (PFE) and BasileaPharmaceutica Ltd. (BSLN) reported that they have completed the licensing contract whereby Pfizer has obtained the exclusive commercialization rights in Europe to CRESEMBA (isavuconazole), a novel anti-fungal treatment for adult patients with diagnosed invasive aspergillosis and mucormycosis, two serious infections associated with high morbidity and mortality among immunocompromised patients. (0-1)
OpGen just signed a development deal with Merck to speed up infectious disease diagnosis by orders of magnitude. Here's how, and why it's so important to the antibiotics sector.
Thermo Fisher Scientific Inc. (NYSE: TMO) just announced that the Food and Drug Administration (FDA) has approved its Oncomine Dx Target Test, a next-generation sequencing test that simultaneously screens tumor samples for biomarkers associated with various available lung cancer therapies. (0-1)
July 18, 2017 - Empery Asset Management, LP has filed a SC 13G form disclosing ownership of 2,500,000 shares of OpGen, Inc. (NASDAQ:OPGN) corresponding to 5.49 percent ownership .
* Opgen Inc - priced a public offering to issue and sell 18.2 million units at an offering price per unit of $0.40 Source: (bit.ly/2tUCOHV) Further company coverage:
July 13, 2017: Here are four stocks trading with heavy volume among 60 equities making new 52-week lows in Thursday’s session. On the NYSE, advancers led decliners by less than 8 to 7 and on the Nasdaq, decliners led advancers by about the same ratio.
GAITHERSBURG, Md., July 13, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announces the pricing of a public offering of an aggregate of 25,000,000 units. Each unit is comprised of one share of common stock (or common stock equivalent) and one common warrant to purchase one share of common stock. The units are being offered at a price of $0.40 per unit.
July 12, 2017: Here are four stocks trading with heavy volume among 73 equities making new 52-week lows in Wednesday’s session. On the NYSE, advancers led decliners by nearly 4 to 1 and on the Nasdaq, advancers led decliners by about 3 to 1.
GAITHERSBURG, Md., June 19, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that it has entered into a global supply agreement to use Thermo Fisher Scientific’s technology to support the commercialization of its rapid molecular products and informatics system to help combat multidrug-resistant infections. OpGen will combine Thermo Fisher’s real-time PCR solutions with its genomic analysis and bioinformatics technology to help healthcare providers rapidly and accurately identify bacterial antibiotic susceptibility using resistance gene profiles.
Good afternoon, and welcome to the OpGen, Inc's First Quarter 2017 Financial Results Conference Call. At this time all, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a q-and-a session. As a reminder, this call is being recorded. I would like to turn the call over to Cammy Duong. Please proceed.
Stock Research Report
OpGen was incorporated in Delaware in 2001. The Company’s headquarters are in Gaithersburg, Maryland, and its principal operations are in Gaithersburg, Maryland and Woburn, Massachusetts. The Company also has operations in Copenhagen, Denmark. The Company operates in one business segment.
OpGen is a precision medicine company using molecular diagnostics and informatics to help combat infectious disease. The Company is developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections.
The Company’s molecular diagnostics and informatics...
2017-10-28 - Wilton
2017-10-25 - Wilton
2017-10-10 - Wilton
2017-10-09 - Wilton
2017-08-25 - Wilton